These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21528891)

  • 21. De-novo designed library of benzoylureas as inhibitors of BCL-XL: synthesis, structural and biochemical characterization.
    Brady RM; Vom A; Roy MJ; Toovey N; Smith BJ; Moss RM; Hatzis E; Huang DC; Parisot JP; Yang H; Street IP; Colman PM; Czabotar PE; Baell JB; Lessene G
    J Med Chem; 2014 Feb; 57(4):1323-43. PubMed ID: 24456288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological activities of new di- and trimeric quinoline derivatives.
    Broch S; Hénon H; Debaud AL; Fogeron ML; Bonnefoy-Bérard N; Anizon F; Moreau P
    Bioorg Med Chem; 2010 Oct; 18(19):7132-43. PubMed ID: 20800501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
    Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
    J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cell death machinery controlled by Bax and Bcl-XL is evolutionarily conserved in Ciona intestinalis.
    Takada N; Yamaguchi H; Shida K; Terajima D; Satou Y; Kasuya A; Satoh N; Satake M; Wang HG
    Apoptosis; 2005 Dec; 10(6):1211-20. PubMed ID: 16215691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamics of the BH3-Only Protein Binding Interface of Bcl-xL.
    Liu X; Beugelsdijk A; Chen J
    Biophys J; 2015 Sep; 109(5):1049-57. PubMed ID: 26331262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction of a three-dimensional pharmacophore for Bcl-2 inhibitors by flexible docking and the multiple copy simultaneous search method.
    Zheng CH; Zhou YJ; Zhu J; Ji HT; Chen J; Li YW; Sheng CQ; Lu JG; Jiang JH; Tang H; Song YL
    Bioorg Med Chem; 2007 Oct; 15(19):6407-17. PubMed ID: 17629704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and computational studies of inhibitors of Bcl-XL.
    Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW
    J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptosis regulators.
    Harada H; Grant S
    Rev Clin Exp Hematol; 2003 Jun; 7(2):117-38. PubMed ID: 14763159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosis.
    Han J; Modha D; White E
    Oncogene; 1998 Dec; 17(23):2993-3005. PubMed ID: 9881701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis.
    Rudner J; Elsaesser SJ; Müller AC; Belka C; Jendrossek V
    Biochem Pharmacol; 2010 Jan; 79(1):10-20. PubMed ID: 19665451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bcl-2 family proteins as targets for anticancer drug design.
    Huang Z
    Oncogene; 2000 Dec; 19(56):6627-31. PubMed ID: 11426648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deciphering the crucial molecular properties of a series of Benzothiazole Hydrazone inhibitors that targets anti-apoptotic Bcl-xL protein.
    Marimuthu P; Balasubramanian PK; Singaravelu K
    J Biomol Struct Dyn; 2018 Aug; 36(10):2654-2667. PubMed ID: 28793831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
    Levoin N; Vo DD; Gautier F; Barillé-Nion S; Juin P; Tasseau O; Grée R
    Bioorg Med Chem; 2015 Apr; 23(8):1747-57. PubMed ID: 25797160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Structural Biology of Bcl-x
    Lee EF; Fairlie WD
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of single disulfide linkages in the folding and activity of scyllatoxin-based BH3 domain mimetics.
    Arachchige D; Margaret Harris M; Coon Z; Carlsen J; Holub JM
    J Pept Sci; 2017 May; 23(5):367-373. PubMed ID: 28326661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL.
    Kellici TF; Chatziathanasiadou MV; Lee MS; Sayyad N; Geromichalou EG; Vrettos EI; Tsiailanis AD; Chi SW; Geromichalos GD; Mavromoustakos T; Tzakos AG
    Org Biomol Chem; 2017 Sep; 15(37):7956-7976. PubMed ID: 28902204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting anti-apoptotic Bcl2 proteins with scyllatoxin-based BH3 domain mimetics.
    Harris MM; Coon Z; Alqaeisoom N; Swords B; Holub JM
    Org Biomol Chem; 2016 Jan; 14(2):440-446. PubMed ID: 26563651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL.
    Wan KF; Wang S; Brown CJ; Yu VC; Entzeroth M; Lane DP; Lee MA
    Cell Cycle; 2009 Dec; 8(23):3943-52. PubMed ID: 19901550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects.
    Opydo-Chanek M; Gonzalo O; Marzo I
    Biochem Pharmacol; 2017 Jul; 136():12-23. PubMed ID: 28288819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of new inhibitors of Bax/Bcl-xL interaction in cancer cells.
    Vo DD; Gautier F; Barillé-Nion S; Juin P; Levoin N; Grée R
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1758-61. PubMed ID: 24602902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.